SIGNATUREFD, LLC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 178 filers reported holding CRISPR THERAPEUTICS AG in Q1 2019. The put-call ratio across all filers is 1.73 and the average weighting 0.6%.

Quarter-by-quarter ownership
SIGNATUREFD, LLC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$96,408
-9.0%
2,124
+12.5%
0.00%0.0%
Q2 2023$105,992
+23.0%
1,888
-0.9%
0.00%
+50.0%
Q1 2023$86,175
+27.6%
1,905
+14.7%
0.00%0.0%
Q4 2022$67,520
-48.8%
1,661
-18.0%
0.00%
-60.0%
Q3 2022$132,000
+22.2%
2,025
+14.3%
0.01%
+25.0%
Q2 2022$108,000
-5.3%
1,772
-2.0%
0.00%
+33.3%
Q1 2022$114,000
+103.6%
1,809
+144.5%
0.00%
+50.0%
Q4 2021$56,000
-46.7%
740
-20.9%
0.00%
-50.0%
Q3 2021$105,000
-72.7%
935
-60.5%
0.00%
-73.3%
Q2 2021$384,000
+28.0%
2,370
-3.7%
0.02%
+15.4%
Q1 2021$300,000
+114.3%
2,460
+168.9%
0.01%
+85.7%
Q4 2020$140,000
+109.0%
915
+14.4%
0.01%
+75.0%
Q3 2020$67,000
+4.7%
800
-7.5%
0.00%0.0%
Q2 2020$64,000
+60.0%
865
-8.0%
0.00%
+33.3%
Q1 2020$40,000
-2.4%
940
+41.4%
0.00%0.0%
Q4 2019$41,000
+51.9%
6650.0%0.00%
+50.0%
Q3 2019$27,000
-12.9%
6650.0%0.00%
-33.3%
Q2 2019$31,000
+29.2%
665
-2.9%
0.00%
+50.0%
Q1 2019$24,000
+41.2%
685
+14.2%
0.00%0.0%
Q4 2018$17,000
-83.3%
600
-73.9%
0.00%
-80.0%
Q3 2018$102,000
-26.1%
2,300
-2.1%
0.01%
-33.3%
Q2 2018$138,000
+187.5%
2,350
+123.8%
0.02%
+150.0%
Q1 2018$48,0001,0500.01%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2019
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders